|Bid||0.00 x 1400|
|Ask||7.95 x 1400|
|Day's Range||6.66 - 6.95|
|52 Week Range||4.42 - 9.75|
|Beta (3Y Monthly)||2.16|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Big Pharma is rapidly increasing its investments into biotech companies aiming to treat disease by targeting the microbiome. Some are also working on using bacterial strains as drugs.
Microbiome-focused biotech Seres Therapeutics is teaming up with drug giant AstraZeneca to explore how the trillions of bacteria in a person’s gut could help fight cancer.
Roger Pomerantz has been the CEO of Seres Therapeutics, Inc. (NASDAQ:MCRB) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 5.26% and -61.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 1.45% and -11.56%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 68 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
Often, publicly-traded companies that trade in discount-bin valuations are there for a reason. When it becomes clear that success is no longer probable, astute investors bail, leaving others holding the bag.